Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) released its quarterly earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Down 11.5 %

Shares of Anebulo Pharmaceuticals stock opened at $1.85 on Thursday. The firm has a market capitalization of $47.98 million, a PE ratio of -5.00 and a beta of -1.01. The stock’s fifty day moving average is $2.05 and its 200-day moving average is $2.35. Anebulo Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $3.61.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.